MedPath

A Safety Study of Lenalidomide in Previously Untreated Adult Multiple Myeloma Patients Who Are Not Eligible for Transplant

Active, not recruiting
Conditions
Multiple Myeloma
Interventions
Registration Number
NCT03106324
Lead Sponsor
Celgene
Brief Summary

This post authorization safety study is designed as prospective non interventional study for patients with newly diagnosed multiple myeloma who are not eligible for transplant. The objective is to compare the incidence of cardiovascular events between patients treated with a first-line lenalidomide containing regimen and those treated with a first-line non-lenalidomide containing regimen. Treatment in both cohorts will be done according to standard care. The study will gather risk factor information at baseline and throughout follow-up. Any cardiovascular event occurring will be assessed by an independent committee. Other safety endpoints will be collected through standard procedures. Observation period will be 3 years on treatment, with an additional evaluation of cardiovascular events 6 months' post treatment and a follow up period until 5 years after inclusion. During follow up the incidence of second primary malignancies (SPM) and overall survival will be assessed.

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
911
Inclusion Criteria
  1. Must have understood and voluntarily signed the Informed Consent Form (ICF)
  2. Age ≥ 18 years at the time of signing the ICF
  3. Newly diagnosed with multiple myeloma
  4. Must not be eligible for transplant
  5. Will be treated with a first-line lenalidomide-containing or nonlenalidomide-containing regimen, or currently is being treated with a first-line regimen and has received less than 2 cycles.
Exclusion Criteria
  1. Prior treatment for Monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma with lenalidomide, thalidomide, or pomalidomide or any agent considered to be a first-line Multiple myeloma (MM) therapy.
  2. Prior treatment with lenalidomide, thalidomide, or pomalidomide or any agent considered to be a first-line MM therapy through clinical trial participation or patient access program
  3. Two or more complete cycles of first-line therapy or any agent considered to be a firstline MM therapy for newly diagnosed multiple myeloma (NDMM) treatment before study enrollment
  4. Refusal to participate in the Revlimid Transplant noneligible (TNE) Newly diagnosed multiple myeloma (NDMM) Post-authorization safety study (PASS) or current participation in the treatment phase of an interventional clinical trial.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
TNE NDMM patients treated with lenalidomide regimenRevlimid (lenalidomide)Newly diagnosed multiple myeloma patients who are not eligible for transplant and who are treated with a first-line regimen containing lenalidomide
TNE NDMM patients treated with non-lenalidomideRevlimid (lenalidomide)Newly diagnosed multiple myeloma patients who are not eligible for transplant and who are treated with a first-line regimen not containing lenalidomide
Primary Outcome Measures
NameTimeMethod
Incidence of cardiovascular eventsApproximately 8 years

Number of participants with cardiovascular adverse events

Secondary Outcome Measures
NameTimeMethod
Incidence of renal impairment in NDMM patientsApproximately 8 years

To document renal function among TNE NDMM patients treated with a first-line regimen

Incidence of Second primary malignancy (SPM) in TNE NDMM patients treated with any first line regimenApproximately 8 years

Secondary primary malignancies will be categorized according to whether they are invasive and non-invasive malignancies.

Incidence of infections in NDMM patientsApproximately 8 years

To document the severity of infections among TNE NDMM patients treated with a first-line regimen.

Trial Locations

Locations (124)

AZ Nikolaas

🇧🇪

Sint Niklass, Belgium

CHU du Mont-Godinne

🇧🇪

Yvoir, Belgium

Nij Smellinghe

🇳🇱

Drachten, Netherlands

Catharina Hospital, Hemato-Oncology

🇳🇱

Eindhoven, Netherlands

Ziekehuis Oost Limburg

🇧🇪

Limburg, Belgium

CHPLT Verviers

🇧🇪

Verviers, Belgium

Cliniques Universitaires Saint-Luc

🇧🇪

Bruxelles, Belgium

CHU Ambroise Pare

🇧🇪

Mons, Belgium

Midlands Regional Hospital , Hematology/Oncology

🇮🇪

Country Offaly, Ireland

Röpcke-Zweers Hospital

🇳🇱

Hardenberg, Netherlands

Innsbruck University Hospital

🇦🇹

Innsbruck, Austria

UZ Gent

🇧🇪

Gent, Belgium

Waterford Regional Hospital, Waterford

🇮🇪

Waterford, Ireland

Helse Førde HF sentralsjukehuset

🇳🇴

Førde, Norway

Akershus universitetssykehus HF

🇳🇴

Lørenskog, Norway

Admiraal de Ruyter Hospital

🇳🇱

Goes, Netherlands

Academic Hospital Maastricht

🇳🇱

Maastricht, Netherlands

UO di Ematologia Osp. Perrino

🇮🇹

Brindisi, Italy

AO Garibaldi Catania - Via Palermo 636

🇮🇹

Catania, Italy

Ospedale Ivrea , Areas Medica

🇮🇹

Ivrea, Italy

Ospedale dell'Angelo

🇮🇹

Mestre, Italy

ASST Grande Ospedale Metropolitano Niguarda - Piazza Ospedale Maggiore, 3 -

🇮🇹

Milano, Italy

Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico

🇮🇹

Milan, Italy

Opsedale di Bolzano

🇮🇹

Milan, Italy

Ospedale Maggiore di Novara

🇮🇹

Novara, Italy

UO Ematologia e Centro Trapianti di Midollo Osseo dell'Ospedale San Francesco di Nuoro

🇮🇹

Nuoro, Italy

IRCCS Policlinico di Pavia

🇮🇹

Pavia, Italy

S.C. Ematologia, Dip.to Oncologico e Tecnologie Avanzate

🇮🇹

Reggio-Emilia, Italy

A.O Bianchi Melacrino Morelli - Presidio Riuniti

🇮🇹

Regio Calabria, Italy

Ospedale Sant'Eugenio

🇮🇹

Rome, Italy

Policlinico Gemelli Roma

🇮🇹

Rome, Italy

Ospedale di Circolo, Fondazione Macchi

🇮🇹

Varese, Italy

CHU-Charleroi

🇧🇪

Charleroi, Belgium

AZ Groeninge

🇧🇪

Kortijk, Belgium

Hospital Prive Sevigne

🇫🇷

Cesson-Sevigne, France

GHM Institut Daniel Hollard

🇫🇷

Grenoble, France

Clinique Victor Hugo

🇫🇷

Le Mans, France

LKH Hochsteiermark

🇦🇹

Leoben, Austria

CHU Saint-Pierre

🇧🇪

Bruxelles, Belgium

Ospedale di Ivrea

🇮🇹

Chivasso, Corso Galileo Ferraris, 3 Chivasso, Italy

Centro di Riferimento Oncologico di Aviano

🇮🇹

Avianno, Italy

Polyclinique Bordeaux Nord Aquaitaine

🇫🇷

Bordeaux, France

CHR Orleans

🇫🇷

Orléans, France

Hospital Prive de Villeneuve d'Ascq

🇫🇷

Villeneuve d'Ascq, France

Charité - Universitätsmedizin Berlin - Campus Benjamin Franklin

🇩🇪

Berlin, Germany

CHR Citadelle Liège

🇧🇪

Liege, Belgium

Odense Hospital

🇩🇰

Odense, Denmark

Hôpital privé d'Antony - Ramsay Générale de Santé

🇫🇷

Antony, France

CH de Libourne

🇫🇷

Libourne, France

CH Mont de Marsan

🇫🇷

Mont de Marsan, France

CH St Jean

🇫🇷

Perpignan, France

Centre Hospitalier Universitaire (CHU) de Saint-Etienne - Hopital Nord

🇫🇷

Saint-Etienne, France

UO di Ematologia Osp. Mons Di Miccolis

🇮🇹

Barletta, Italy

Ospedale Alessandria, Via Venezia, 16, 15121 Alessandria AL

🇮🇹

Allessandria, Italy

Ospedale di Circolo di Busto Arsizio

🇮🇹

Busto Arsizio, Italy

ASST Grande Ospedale Metropolitano Niguarda

🇮🇹

Milan, Italy

UO di Ematologia Osp. S. Carlo - Potenza

🇮🇹

Potenza, Italy

Servizio immunoematologia e medicina trasfusionale-ASP

🇮🇹

Ragusa, Italy

UOSD Ematologia Complesso Opsedaliero-Ospedale S. Spirito e Nuovo Regina Margherita

🇮🇹

Rome, Italy

Ospedale Belcolle Viterbo

🇮🇹

Viterbo, Italy

VieCuri Medical Center

🇳🇱

Venlo, Netherlands

Rode Kruis Hospital

🇳🇱

Beverwijk, Netherlands

Istituto di Ematologia ed Ocnologia Medica "Seràgnoli" AUO Sant'Orsola - Bologna

🇮🇹

Bologna, Italy

Dipartimento di Oncologia Medica e Chirurgica AORN S. Anna e S. Sebastiano

🇮🇹

Caserta, Italy

"S.C. di Ematologia e Centro Trapianti di Cellule Staminali Emopoietiche

🇮🇹

Cagliari, Italy

AO Garibaldi Catania

🇮🇹

Catania, Italy

Skåne University Hospital, Lund

🇸🇪

Lund, Sweden

Worcestershire Acute Hospitals NHS Trust - Worcestershire Royal Hospital

🇬🇧

Worcester, United Kingdom

Hospital Santa Lucía

🇪🇸

Cartagena, Spain

Northern Health and Social Care Trust -Antrim Area Hospital

🇬🇧

Antrim, United Kingdom

South Eastern Health and Social Care Trust - The Ulster Hospital

🇬🇧

Belfast, United Kingdom

St Georges Hospital

🇬🇧

London, United Kingdom

Queen Alexandra Hospital - Portsmouth Hospitals NHS Trust

🇬🇧

Cosham, United Kingdom

Lincoln County Hospital

🇬🇧

Lincoln, United Kingdom

Norfolk and Norwich University Hospital

🇬🇧

Norfolk, United Kingdom

Royal Stoke Hospital

🇬🇧

Stoke-on-Trent, United Kingdom

The Clatterbridge Cancer Centre NHS Foundation Trust - The Royal Liverpool Hospital

🇬🇧

Liverpool, United Kingdom

Southend Hospital

🇬🇧

Southend-on-Sea, United Kingdom

Medizinische Klinik II, DONAUISAR Klinikum Deggendorf, Akademisches Lehrkrankenhaus der Medizinischen Hochschule Hannover

🇩🇪

Deggendorf, Germany

Onkologie Koln

🇩🇪

Koln, Germany

Kliniken Berlin Köpenick

🇩🇪

Berlin, Germany

St. Bernward Krankenhaus GmbH

🇩🇪

Hildesheim, Germany

Dres. Neise & Lollert, Praxis für Hämatologie & Onkologie

🇩🇪

Krefeld, Germany

Onko-Log Mulheim Gbr

🇩🇪

Mulheim, Germany

Klinikum Magdeburg

🇩🇪

Magdeburg, Germany

MVZ Mitte - Onkologische Schwerpunktpraxis

🇩🇪

Leipzig, Germany

Internistische Facharztzentrum mit Dialyse

🇩🇪

Memmingen, Germany

Medizinisches Zentrum für Hämatologie und Onkologie München MVZ GmbH

🇩🇪

Munchen, Germany

Stauferklinikum

🇩🇪

Mutlangen, Germany

Klinikum Nord, Klinik für Innere Medizin 5

🇩🇪

Nurnberg, Germany

Onkologische Praxis Oldenburg

🇩🇪

Oldenburg, Germany

Das Diak

🇩🇪

Schwabisch Hall, Germany

Ueboroertliche Berugsausuebungsgemeinschaft

🇩🇪

Troisdorf, Germany

Klinikum Sindelfingen, Med.Klinik I

🇩🇪

Sindelfingen, Germany

Onkologicum Stuttgart

🇩🇪

Stuttgart, Germany

Lahn-Dill-Kliniken

🇩🇪

Wetzlar, Germany

Hämatologie / Internistische Onkologie

🇩🇪

Wiesbaden, Germany

Hospital de Jerez

🇪🇸

Cadiz, Spain

IP HULA

🇪🇸

Lugo, Spain

Hospital Manises

🇪🇸

Valencia, Spain

Hospital Universitario Quironsalud Madrid

🇪🇸

Madrid, Spain

Complejo Universitario Navarra

🇪🇸

Pamplona, Spain

Hospital Universitario Central Asturias

🇪🇸

Oviedo, Spain

Kliniken Villingen-Schwenningen

🇩🇪

Villingen-Schwenningen, Germany

Gemeinschaftpraxis Pott/Tirier/Hannig

🇩🇪

Bottrop, Germany

HELIOS Klinikum Berlin Buch

🇩🇪

Berlin, Germany

University hospital St. Pölten

🇦🇹

Polten, Austria

Aalborg University Hospital

🇩🇰

Aalborg, Denmark

CH Victor Dupouy

🇫🇷

Argenteuil, France

CHU de Nice

🇫🇷

Nice, France

Sozialstiftung Bamberg

🇩🇪

Bamberg, Germany

Charité - Universitätsmedizin Berlin - Campus Charité Mitte

🇩🇪

Berlin, Germany

W8 Praxis für Onkologie

🇩🇪

Aachen, Germany

Klinikum St. Marien Amberg

🇩🇪

Amberg, Germany

Stadt. Krankenhaus Kiel, 2.med Klinik,

🇩🇪

Kiel, Germany

Lübecker Onkologische Schwerpunktpraxis

🇩🇪

Lubeck, Germany

Kreiskliniken Reutlingen

🇩🇪

Reutlingen, Germany

Ospdeale Policlinico Borgo Roma

🇮🇹

Verona, Italy

Son Espases

🇪🇸

Palma de Mallorca, Spain

Hospital de Jaen

🇪🇸

Jaen, Spain

Birmingham Heartlands Hospital

🇬🇧

Birmingham, United Kingdom

Betsi Cadwaladr University Health Board - Glan Clwyd Hospital

🇬🇧

Bodelwyddan, United Kingdom

Southmead Hospital -North Bristol NHS Trust

🇬🇧

Bristol, United Kingdom

University Medical Center Utrecht

🇳🇱

Utrecht, Netherlands

© Copyright 2025. All Rights Reserved by MedPath